Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NA-831 and Combinations for COVID-19 Treatment (NATADEX)
NCT04452565Phase 3
Key facts
- Status
- Unknown
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Countries
- 1
- Sponsor
- Biomed Industries
- Modality
- Small Molecules
- Drugs
- cyclo(prolylglycyl)
- Conditions
- coronavirus disease 2019 (COVID-19)
01
Overview
Phase 3, randomised, open-label trial of cyclo(prolylglycyl) in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Biomed Industries. Primary endpoint: Time to recovery at 36 days. Status: unknown.
02
Design
4 arms- Study design
- RandomizedOpen-label
NA-831 Alone
NA-831 30-60mg orally for 5 days
NA-831 + Atazanavir
NA-831 + Atazanavir for 5 days
NA-831 + Dexamethasone
NA-831 + Dexamethasone for 5 days
Atazanavir + Dexamethasone
Atazanavir + Dexamethasone for 5 days
03
Endpoints
Primary
Time to recovery
Secondary
Time to fever resolution
Beyond the preview
Go deeper on NCT04452565.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04452565.